JP2023027269A5 - - Google Patents

Download PDF

Info

Publication number
JP2023027269A5
JP2023027269A5 JP2022199122A JP2022199122A JP2023027269A5 JP 2023027269 A5 JP2023027269 A5 JP 2023027269A5 JP 2022199122 A JP2022199122 A JP 2022199122A JP 2022199122 A JP2022199122 A JP 2022199122A JP 2023027269 A5 JP2023027269 A5 JP 2023027269A5
Authority
JP
Japan
Prior art keywords
purin
cyclohexanecarboxamide
ylamino
chloro
difluorophenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022199122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023027269A (ja
Filing date
Publication date
Priority claimed from JP2017538172A external-priority patent/JP6884701B2/ja
Application filed filed Critical
Publication of JP2023027269A publication Critical patent/JP2023027269A/ja
Publication of JP2023027269A5 publication Critical patent/JP2023027269A5/ja
Pending legal-status Critical Current

Links

JP2022199122A 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 Pending JP2023027269A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
JP2017538172A JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021195105A Division JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Publications (2)

Publication Number Publication Date
JP2023027269A JP2023027269A (ja) 2023-03-01
JP2023027269A5 true JP2023027269A5 (enExample) 2023-03-08

Family

ID=55632334

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017538172A Active JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2022199122A Pending JP2023027269A (ja) 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017538172A Active JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Country Status (28)

Country Link
US (8) US9512124B2 (enExample)
EP (2) EP3204386B1 (enExample)
JP (4) JP6884701B2 (enExample)
KR (2) KR102504849B1 (enExample)
CN (2) CN113248506A (enExample)
AR (2) AR102171A1 (enExample)
AU (2) AU2015328414B2 (enExample)
CA (1) CA2963639C (enExample)
CL (1) CL2017000820A1 (enExample)
CO (1) CO2017003838A2 (enExample)
CY (1) CY1124173T1 (enExample)
DK (1) DK3204386T3 (enExample)
EA (1) EA201790779A1 (enExample)
EC (1) ECSP17026210A (enExample)
ES (2) ES2871142T3 (enExample)
HR (1) HRP20210656T1 (enExample)
HU (1) HUE054694T2 (enExample)
IL (2) IL251566B (enExample)
LT (1) LT3204386T (enExample)
MX (2) MX388321B (enExample)
PL (1) PL3204386T3 (enExample)
PT (1) PT3204386T (enExample)
RS (1) RS61884B1 (enExample)
SG (2) SG10202009598VA (enExample)
SI (1) SI3204386T1 (enExample)
SM (1) SMT202100302T1 (enExample)
TW (1) TW201629063A (enExample)
WO (1) WO2016057370A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113248506A (zh) * 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
CN108137609B (zh) 2015-08-03 2021-07-16 百时美施贵宝公司 用作TNFα的调节剂的环状化合物
CN109069512B (zh) * 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
PT3436019T (pt) * 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
WO2017210399A1 (en) * 2016-06-02 2017-12-07 Celgene Corporation Animal and human anti-malarial agents
CN109476696B (zh) * 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
CN111432841A (zh) 2017-10-04 2020-07-17 细胞基因公司 顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的组合物和使用方法
US10590136B2 (en) 2017-10-04 2020-03-17 Celgene Corporation Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
EP1951693A4 (en) 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
NZ589053A (en) 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN113248506A (zh) 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Similar Documents

Publication Publication Date Title
JP2023027269A5 (enExample)
JP2017530199A5 (enExample)
RU2469032C2 (ru) Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
HRP20210656T1 (hr) Supstituirani spojevi aminopurina, njihovi sastavi, te postupci liječenja istima
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
RU2017121958A (ru) Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
JP6411895B2 (ja) 治療活性化合物およびその使用方法
JP2012506446A5 (enExample)
JP5508265B2 (ja) 多発性硬化症の治療のための、スフィンゴシン1−ホスフェート(s1p)受容体に結合する6−アミノ−ピリミジン−4−カルボキサミド誘導体及び関連化合物
ES2523266T5 (es) Derivados de piridina y pirimidina ortocondensados (por ejemplo, purinas) como inhibidores de proteínas quinasas
CN1823063B (zh) 作为磷酸二酯酶抑制剂的喹啉衍生物
JP2011518158A5 (enExample)
JP2006509748A5 (enExample)
JP2018522823A5 (enExample)
JP2008509910A5 (enExample)
IL267743A (en) Mutant Isocetrate Dehydrogenase Suppressant Compounds, Preparations and Uses
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
JP2017529346A5 (enExample)
RU2005119151A (ru) Производные пиридазинона в качестве gsk-3бета-ингибиторов
JP2015529224A5 (enExample)
JP2013544893A5 (enExample)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2016533397A5 (enExample)
IL259975A (en) Pyridine compounds are converted to 4-phenyl as unsystematic trg5 agonists
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний